Orgentec Diagnostika Acquires U.S. Diagnostic Test Maker Corgenix for $16 Million

September 2, 2014

German manufacturer Orgentec Diagnostika has acquired Broomfield, Colo.-based Corgenix Medical in a $16 million deal that will bolster both companies’ portfolios of specialty diagnostic assays, the companies announced Tuesday.

Together the companies will offer more than 350 tests, mostly enzyme-linked immunosorbent assays, or ELISA, which are used to diagnose immunologic disorders, vascular and infectious diseases, bone and joint disorders and impaired organ functions. Corgenix also produces the world’s only nonblood-based test for aspirin effect and is developing a quick test for the Ebola virus, which is now raging in several countries in West Africa.

The transaction — which is expected to close in the fourth quarter of this year — will also extend the companies’ global distribution networks. As a subsidiary of Orgentec, Corgenix will retain its Colorado headquarters, giving the German firm an immediate presence in the U.S. in vitro diagnostic test market.

In addition to the U.S., the combined company will serve hospitals and laboratories throughout Europe, Asia, Latin America and the Middle East. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.